All In Biotech

Drug Trial Radar · NCT05997615

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Participants With Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

347

Planned (sponsor's estimate)

Start

Aug 10, 2023

Primary completion

Sep 30, 2027

Study completion Jun 30, 2030

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
Collaborators
Vir Biotechnology, Inc.
First posted
Aug 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There are many treatment options for men with various stages of prostate cancer. Some treatments work well for a while but can cause medical problems in some men. Also, the cancer may come back after treatment. This is an early development study of VIR-5500 in men with prostate cancer. In this study, VIR-5500 will be given to people for the first time. VIR-5500 will either be given by itself or given together with one or more standard cancer treatments: enzalutamide, darolutamide and docetaxel. Some other cancer treatments may also be given with VIR-5500 during this study, depending on results from other ongoing studies. Early development studies are mostly about safety, but also to find the most suitable dose. Other aims are to check if VIR-5500 shows signs of reducing tumor growth and to learn how the body processes VIR-5500. This will be done both for VIR-5500 given by itself and given together with the other cancer treatments. The main aim(s) of the study are to check the safety of different doses of VIR-5500 when given by itself and given together with the standard cancer treatments, and how well it is tolerated; to find a suitable dose of VIR-5500 when given by itself and given together with the standard cancer treatments; to check the safety of VIR-5500 when given by itself to people in China and Japan; and to check how well VIR-5500 controls tumors when given by itself and given together with the standard cancer treatments. Adult men with certain types of advanced prostate cancer can take part. Their cancer has spread to other parts of the body (metastatic). The different types of cancer in this study are: Metastatic hormone-sensitive prostate cancer (mHSPC). Prostate cancer that needs testosterone to grow; Metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer that continues to grow even when testosterone levels are low; and High-risk biochemical recurrent prostate cancer (high-risk BRPC). Biochemical recurrence is a rise in PSA levels after treatment for prostate cancer. Men whose PSA levels double in less than 1 year are considered high risk of the cancer coming back and quickly getting worse. In this study, VIR-5500 will be given to people for the first time. VIR-5500 will either be given itself or given together with at least one of the standard cancer treatments: enzalutamide, darolutamide, and docetaxel. The standard cancer treatment given will depend on which part of the study the men are in, and what type of prostate cancer they have. Other cancer treatments may be given, depending on results from other ongoing studies. The study will have 4 parts. In Part 1, different small groups of men with Metastatic castration-resistant prostate cancer (mCRPC) will receive lower to higher doses of VIR-5500 given by itself. Any medical problems will be recorded for each dose. This is to find out suitable doses to use in Part 2 of the study. In Part 2, other small groups of men with mCRPC will receive the suitable doses of VIR-5500 worked out from Part 1. These men will have previously received specific cancer treatments before starting this study. In Part 3, other different small groups of men with metastatic hormone-sensitive prostate cancer (mHSPC), mCRPC or high-risk BRPC will receive lower to higher doses of VIR-5500 given by itself or given with the other standard cancer treatments. They will be given VIR-5500 with enzalutamide or darolutamide, VIR-5500 with docetaxel, VIR-5500 with docetaxel and enzalutamide, or VIR- 5500 with docetaxel and darolutamide. Any medical problems will be recorded for each dose. This is to find out suitable doses to use in Part 4 of the study. In Part 4, other small groups of men with mHSPC, mCRPC or high-risk biochemical recurrent prostate cancer (BRPC) will receive the suitable doses of VIR-5500 given together with the standard cancer treatments, worked out in Part 3. They will be given VIR-5500 with enzalutamide, VIR-5500 with darolutamide, VIR-5500 with docetaxel and enzalutamide, or VIR-5500 with docetaxel and darolutamide. The standard cancer treatment given will depend on their previous treatment before joining the study and the type of prostate cancer they have.

Conditions

  • Hormone-refractory Prostate Cancer

Interventions

  • VIR-5500Drug

    Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion

  • Androgen receptor signaling inhibitor (ARSI)Drug

    Oral administration

  • DocetaxelDrug

    Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1, 1a, 2a and Part 3: Number of Participants With Adverse Events (AEs) (mCRPC, mHSPC and BRPC)Time frame: Up to 80 months
  2. Part 1, 1a, 2a and Part 3: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (mCRPC, mHSPC and BRPC)Time frame: Up to 80 months
  3. Part 1, 1a and Part 3: Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Up to 28 Days
  4. Part 2 and 4: Prostate-Specific Antigen (PSA) Response Rate (PSA50) (mCRPC and mHSPC)Time frame: Up to 80 months
  5. Part 2 and 4: Objective Response Rate (ORR) (mCRPC and mHSPC)Time frame: Up to 80 months
  6. Part 4: PSA50 Response Rate (BRPC)Time frame: Up to 80 months
  7. Part 4: Duration of PSA50 Response (BRPC)Time frame: Up to 80 months

Locations

30 sites in 5 countries. Site status is shown where the registry gives one.

  • Duarte Cancer Center

    Duarte, California · Recruiting

  • University of California Irvine

    Irvine, California · Recruiting

  • Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • UCI Health Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Stanford University

    Palo Alto, California · Recruiting

  • University of California

    San Francisco, California · Recruiting

  • Chicago Cancer Center

    Zion, Illinois · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • Site AU61002

    Darlinghurst, Australia · Recruiting

  • Site AU61001

    Melbourne, Australia · Recruiting

  • The Cancer Institute Hospital of JFCR

    Koto-ku, Tokyo, Japan · Recruiting

  • Site ES34001

    Barcelona, Spain · Recruiting

  • Site ES34007

    Barcelona, Spain · Recruiting

  • Site ES34015

    Barcelona, Spain · Withdrawn

  • Site ES34006

    El Palmar, Spain · Recruiting

  • Site ES34010

    Logroño, Spain · Recruiting

  • Site ES34003

    Madrid, Spain · Recruiting

  • Site ES34008

    Madrid, Spain · Recruiting

  • Site ES34012

    Madrid, Spain · Recruiting

  • Site ES34013

    Málaga, Spain · Recruiting

  • Site ES34004

    Pamplona, Spain · Recruiting

  • Site ES34002

    Pozuelo de Alarcón, Spain · Recruiting

  • Site ES34005

    Sabadell, Spain · Recruiting

  • Site ES34009

    Valencia, Spain · Recruiting

  • Site ES34011

    Valencia, Spain · Recruiting

  • Site GB44003

    Leicester, United Kingdom · Recruiting

  • Site GB44001

    London, United Kingdom · Recruiting

  • Site GB44004

    Newcastle, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.